Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394646 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL2394650 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL29542814 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL2394643 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL3125623 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL29582309 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL3125611 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL29542724 | 1.00 | GPR3 (0.44) | GPR3LMNAL3MBTL1NOX1MEN1 | |
| SCHEMBL22159002 | 0.85 | CALM1 (0.38) | GPR3LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL22159001 | 0.85 | CALM1 (0.38) | GPR3LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250269037-A1 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-28 | — | — | US | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | ASTRAZENECA AB (SE) | 2012-11-01 | — | — | US | disclosed |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | BALESTRA MICHAEL (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2391606-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GPR3 3164/4885LMNA 3803/4885L3MBTL1 3097/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | GPR3 4133/4885LMNA 401/4885L3MBTL1 2729/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | GPR3 3141/4885LMNA 4799/4885L3MBTL1 819/4885 |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, HTR5A, TPH2 | GPR3 698/4885LMNA 3875/4885L3MBTL1 3828/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | GPR3 3790/4885LMNA 998/4885L3MBTL1 3542/4885 |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, TPH1, TPH2 | GPR3 1835/4885LMNA 2121/4885L3MBTL1 3899/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | GPR3 2054/4885LMNA 259/4885L3MBTL1 656/4885 |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | TPH1, TPH2, PNMT | GPR3 665/4885LMNA 3739/4885L3MBTL1 3750/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | GPR3 3790/4885LMNA 998/4885L3MBTL1 3542/4885 |
| US-20250269037-A1 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | PAICS, ORC3, SSB | GPR3 3667/4885LMNA 4036/4885L3MBTL1 4756/4885 |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | HTR5A, PNMT, GRIK5 | GPR3 593/4885LMNA 3908/4885L3MBTL1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.